US tariff heat: Fitch says Indian firms face limited direct hit; pharma sector seen at risk if duties widen
Fitch Ratings cautions that while Indian corporates have limited direct exposure to current US tariffs, sectors like pharmaceuticals could face risks if further measures are imposed. The US has levied a 25% tariff on Indian goods since August 7, 2025, with another 25% due on August 27, due to India’s Russian oil imports.🕒 1 min read
Fitch Ratings cautions that while Indian corporates have limited direct exposure to current US tariffs, sectors like pharmaceuticals could face risks if further measures are imposed. The US has levied a 25% tariff on Indian goods since August 7, 2025, with another 25% due on August 27, due to India’s Russian oil imports.
Continue Reading
- Feeling Drained By 4 PM? Tulsi-Ginger Tea May Help Recharge Naturally
-
How Rama Duwaji, Zohran Mamdani’s Wife, Devised A Winning Campaign
-
MS Dhoni Fired Huge ‘Fire Starting To Flicker. Go Out…’ Reminder Amid Uncertain IPL Future
- EXCLUSIVE | IND vs ENG: Arshdeep all set to make his Test debut at Oval
-
Vivek Ramaswamy’s Family Bodyguard Arrested On Drug Trafficking Charges
- Govt asks e-tailers to promote GST rejig
-
Anthropic Sues Pentagon Over ‘Supply-Chain Risk’ Designation
-
Paranormal Investigator Dan Rivera Dies At 54 While Touring With ‘Haunted’ Annabelle Doll
- Tracy Porter and Brett Maxie ignite legacy debate after Saints Hall of Fame induction
-
“His Statement Was Twisted”: Siddaramaiah On Son’s “Political Life” Remark